Boehringer Ingelheim half-year results 2023 Boehringer Ingelheim half-year results 2023 First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
SIRPα Cancer Immunology Research SIRPα Cancer Immunology Research Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Digital innovation: Our digital pipeline is only growing Digital innovation: Our digital pipeline is only growing BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.
Striving to revolutionize mental health research Striving to revolutionize mental health research World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.
Animal Health Partnering Interests Pain & Mobility May 2024 CORP Animal Health Partnering Interests Pain & Mobility May 2024 CORP
supplier_code_of_conduct_2020_FR_bis-2021-04-14.pdf supplier_code_of_conduct_2020_FR_bis-2021-04-14.pdf